TUCSON, Ariz. — HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Ann F. Hanham, Ph.D. has been appointed to its Board of Directors (“Board”).

Ann Hanham is a senior health care executive with experience working with both private and public companies. Dr. Hanham possesses a diverse background in global clinical and regulatory development, finance, and corporate strategy. She has extensive experience in developing pharmaceutical, diagnostic and medical device products with a proven track record of clinical and regulatory approvals, building businesses, and creating shareholder value.

“We are very honored to have Ann join our Board,” said TJ Johnson, President and CEO of HTG Molecular Diagnostics. “Ann’s career experience, industry knowledge and leadership capabilities will be tremendous assets for our Board and management team.”

Dr. Hanham is a founding and managing partner of BAR Capital M